Frederick L Baehner

List of Publications by Year
in descending order

65 papers	18,871 citations	87843 38 h-index	114418 63 g-index
66 all docs	66 docs citations	66 times ranked	19353 citing authors

#	Article	IF	Citations
1	A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. New England Journal of Medicine, 2004, 351, 2817-2826.	13.9	5,646
2	A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell, 2006, 10, 515-527.	7.7	2,729
3	Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptorâ€"Positive Breast Cancer. Journal of Clinical Oncology, 2006, 24, 3726-3734.	0.8	2,369
4	Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncology, The, 2010, 11, 55-65.	5.1	1,252
5	Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study. Journal of Clinical Oncology, 2010, 28, 1829-1834.	0.8	647
6	A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. European Urology, 2014, 66, 550-560.	0.9	553
7	Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Modern Pathology, 2011, 24, 157-167.	2.9	545
8	A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast. Journal of the National Cancer Institute, 2013, 105, 701-710.	3.0	442
9	Breast Cancer Growth Prevention by Statins. Cancer Research, 2006, 66, 8707-8714.	0.4	309
10	Bladder Cancer Outcome and Subtype Classification by Gene Expression. Clinical Cancer Research, 2005, 11, 4044-4055.	3.2	303
11	Î²1 Integrin Inhibitory Antibody Induces Apoptosis of Breast Cancer Cells, Inhibits Growth, and Distinguishes Malignant from Normal Phenotype in Three Dimensional Cultures and In vivo. Cancer Research, 2006, 66, 1526-1535.	0.4	303
12	Relationship Between Tumor Gene Expression and Recurrence in Four Independent Studies of Patients With Stage II/III Colon Cancer Treated With Surgery Alone or Surgery Plus Adjuvant Fluorouracil Plus Leucovorin. Journal of Clinical Oncology, 2010, 28, 3937-3944.	0.8	271
13	Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptorâ€"Positive Breast Cancer. JAMA Oncology, 2018, 4, 545.	3.4	246
14	Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Research and Treatment, 2011, 128, 703-711.	1.1	223
15	Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. Journal of Clinical Oncology, 2015, 33, 3938-3944.	0.8	223
16	Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory. Journal of Clinical Oncology, 2008, 26, 2473-2481.	0.8	212
17	A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Research and Treatment, 2015, 152, 389-398.	1.1	188
18	Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. JAMA Oncology, 2016, 2, 56.	3.4	183

#	Article	IF	Citations
19	Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Research and Treatment, 2010, 119, 137-144.	1.1	179
20	Lobular Neoplasia of the Breast Revisited With Emphasis on the Role of E-Cadherin Immunohistochemistry. American Journal of Surgical Pathology, 2013, 37, e1-e11.	2.1	137
21	Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. Npj Breast Cancer, 2016, 2, 16017.	2.3	125
22	Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Research and Treatment, 2008, 108, 233-240.	1.1	123
23	Genes and pathways downstream of telomerase in melanoma metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 11306-11311.	3.3	121
24	Estrogen Receptor (*ESR1*) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor–Positive Breast Cancer. Journal of Clinical Oncology, 2011, 29, 4160-4167.	0.8	120
25	Human Epidermal Growth Factor Receptor 2 Assessment in a Case-Control Study: Comparison of Fluorescence In Situ Hybridization and Quantitative Reverse Transcription Polymerase Chain Reaction Performed by Central Laboratories. Journal of Clinical Oncology, 2010, 28, 4300-4306.	0.8	113
26	Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Research and Treatment, 2011, 129, 607-616.	1.1	89
27	Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Research and Treatment, 2017, 161, 17-28.	1.1	83
28	A Multimarker Prognostic Assay for Primary Cutaneous Melanoma. Clinical Cancer Research, 2009, 15, 6987-6992.	3.2	80
29	Molecular Predictors of 3D Morphogenesis by Breast Cancer Cell Lines in 3D Culture. PLoS Computational Biology, 2010, 6, e1000684.	1.5	77
30	Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (*ESR1*) on Predicting Late Distant Recurrence Risk in Estrogen Receptor–Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14. Journal of Clinical Oncology, 2016, 34, 2350-2358.	0.8	71
31	Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Research and Treatment, 2012, 134, 683-692.	1.1	69
32	Molecular Drivers of Onco*type* DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study. Journal of Clinical Oncology, 2021, 39, 126-135.	0.8	69
33	21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. Npj Breast Cancer, 2018, 4, 37.	2.3	65
34	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. JAMA Oncology, 2020, 6, 505.	3.4	51
35	Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer. Journal of Clinical Oncology, 2022, 40, 2557-2567.	0.8	49
36	Phosphorylation of the src Epithelial Substrate Trask Is Tightly Regulated in Normal Epithelia but Widespread in Many Human Epithelial Cancers. Clinical Cancer Research, 2009, 15, 2311-2322.	3.2	46

#	Article	IF	Citations
37	Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity. Breast Cancer Research and Treatment, 2011, 130, 635-644.	1.1	44
38	The Transmembrane src Substrate Trask Is an Epithelial Protein that Signals during Anchorage Deprivation. American Journal of Pathology, 2009, 174, 1756-1765.	1.9	39
39	Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. Breast Cancer Research and Treatment, 2012, 135, 913-922.	1.1	39
40	21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology. Breast Cancer Research and Treatment, 2018, 168, 69-77.	1.1	36
41	Differential impact of prognostic parameters in hormone receptorâ€"positive lobular breast cancer. Cancer, 2020, 126, 4847-4858.	2.0	33
42	Genomic signatures of cancer: Basis for individualized risk assessment, selective staging and therapy. Journal of Surgical Oncology, 2011, 103, 563-573.	0.8	32
43	A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer. Advances in Therapy, 2015, 32, 1237-1247.	1.3	32
44	Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial. Journal of the National Cancer Institute, 2017, 109, djw207.	3.0	26
45	Elevated Levels of Proliferating and Recently Migrated Tumor-associated Macrophages Confer Increased Aggressiveness and Worse Outcomes in Breast Cancer. Annals of Surgical Oncology, 2012, 19, 3979-3986.	0.7	24
46	The Prognostic Implications of Macrophages Expressing Proliferating Cell Nuclear Antigen in Breast Cancer Depend on Immune Context. PLoS ONE, 2013, 8, e79114.	1.1	24
47	Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clinical Cancer Research, 2009, 15, 7693-7700.	3.2	23
48	Metastatic Balloon Cell Melanoma. Acta Cytologica, 2005, 49, 543-548.	0.7	22
49	The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831. Breast Cancer Research, 2015, 17, 133.	2.2	21
50	Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer. Clinical Cancer Research, 2011, 17, 7194-7203.	3.2	20
51	The analytical validation of the Oncotype DX Recurrence Score assay. Ecancermedicalscience, 2016, 10, 675.	0.6	20
52	Fetal neurenteric cyst causing hydrops: case report and review of the literature. , 1999, 19, 118-121.		18
53	The run-in phase of the prospective WSG-ADAPT HR+/HER2â€" trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097313.	1.4	18
54	Fine Needle Aspiration Cytology of Intraoral Epithelioid Hemangioma. Acta Cytologica, 2003, 47, 275-280.	0.7	16

#	Article	IF	Citations
55	The Impact of Primary Melanoma Thickness and Microscopic Tumor Burden in Sentinel Lymph Nodes on Melanoma Patient Survival. Annals of Surgical Oncology, 2012, 19, 1034-1042.	0.7	14
56	Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors. Breast Cancer Research and Treatment, 2016, 159, 71-78.	1.1	11
57	MR Imaging Features of Gadofluorine-Labeled Matrix-Associated Stem Cell Implants in Cartilage Defects. PLoS ONE, 2012, 7, e49971.	1.1	10
58	Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies. Advances in Therapy, 2019, 36, 828-841.	1.3	10
59	A Comparison of Predicted Ipsilateral Tumor Recurrence Risks in Patients With Ductal Carcinoma in Situ of the Breast After Breast-Conserving Surgery by Breast Radiation Oncologists, the Van Nuys Prognostic Index, the Memorial Sloan Kettering Cancer Center DCIS Nomogram, and the 12-Gene DCIS Score Assay. Advances in Radiation Oncology, 2021, 6, 100607.	0.6	9
60	Genomic comparison of paired primary breast carcinomas and lymph node macrometastases using the Oncotype DX Breast Recurrence ScoreÂ® test. Breast Cancer Research and Treatment, 2019, 177, 611-618.	1.1	6
61	Fine Needle Aspiration Cytology of Adult Perineal Rhabdomyosarcoma. Acta Cytologica, 2006, 50, 88-92.	0.7	5
62	Accurate Assessment of Human Epidermal Growth Factor Receptor 2. Journal of Clinical Oncology, 2012, 30, 1727-1728.	0.8	3
63	Reply to J.M. Guinebretiere and L. Arnould et al. Journal of Clinical Oncology, 2009, 27, 2734-2735.	0.8	1
64	Molecular-based Testing in Breast Disease for Therapeutic Decisions. , 2012, , 173-188.		1
65	Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatin. Journal of Gastrointestinal Oncology, 2022, 13, 126-136.	0.6	1